High grade sarcoma present a systemic metastatic progression in approximaly 50% of cases. The effectiveness of palliative chemotherapy as a treatment of systemic metastases is still controversed. The main objectif of this study is to assess disease progression and survival of patients diagnosed with metastatic soft tissue sarcomas treated with palliative chemotherapy, analyse chemotherapy treatment patterns and response to different lines of treatment.

Retrospective chart review of 75 patients treated with palliative chemotherapy for metastatic soft tissue sarcomas between 2003 and 2013 at Maisonneuve-Rosemont Hospital. Data for control group of 40 patients with metastatic soft tissue sarcomas not treated with chemotherapy was collected retrospectively. Collected data include demographic data, overall survival, time free survival, type of chemotherapy treatment, surgical treatment and adverse reaction to palliative chemotherapy. Overall survival was analysed with Kaplan-Meier test. Categorial variable were compared with Log-Rank test.

Seventy-five patients (37% female; mean age 50.4 years) received minimally one line of chemotherapy for their metastatic sarcomas. The regimens most commonly used in first-line were doxorubicin (48%) and doxorubicin combined with ifosfamide (21.3%). Favorable response was achieved by 38.7% in first-line and 27.9% in second-line therapy. Median overall survival with chemotherapy treatments was more than two times overall survival without treatments. Median overall survival was 19 months with chemotherapy treatments and 7 months without chemotherapy (p<0.0001). There was no statistically significant difference between survivals for treated and untreated patients with chemotherapy when analysed in term of the histological subtype, age and monotherapy versus combined treatment. Event-free survival was statistically longer during the first year for the group of patients treated with combined chemotherapy (p=0.0125).

Results have shown a significantly improved overall survival in all histological groups, resulting in an OS of 19 vs 7 months for the chemotherpy and non chemotherapy group respectively. Nevertheless, patients with favorable response to chemotherapy have poor outcomes. Additional treatment options are needed.

Background: The exact incidence of cancer (primary/metastatic) leading to pathological fracture in femoral neck is not clear. Bone specimen is often sent for histology in suspicious cases. This retrospective study was aimed to answer the above question and to review our hospital practice in managing these patients.

Materials & Methods: All patients with fracture neck of femur undergoing surgery and had bone specimen taken for histo-pathological examination between 01.01.2002 and 31.12.2003 were included. Case notes and histology reports were reviewed.

Results: Out of total 533 patients with femoral neck fracture, 32 (6%) patients had bone specimen taken for histology. 9 male & 23 female patients with mean age of 82 years. 58% had past history of cancer (commonest being breast) with/without suspicious lesion on x-rays where as the remaining had no history of cancer but suspicious lesion on x-rays. 4 (12.5%) had positive histology results. All four had metastatic disease (2 from breast, 1 from renal and 1from multiple myeloma). Only 19% had results documented in case notes but 81% had reports filed in notes. Appropriate referral was made to oncology team for three patients. The fourth patient with multiple myeloma died in hospital before the referral. Four of 28 (14%) patients with negative results died within 3 years following the surgery compared to only 1 (multiple myeloma) out of 4 patients with positive results.

Conclusion: The incidence of suspicious pathological femoral neck fracture was 6% but incidence of cancer was 0.7%. All positive cases were metastatic. Commonest primary was from breast – adenocarcinoma). Mortality in negative cases was 16% at average of 3 years compared to 25% in metastatic fracture patients.

Introduction: It was noted that INR levels transiently increased before dropping after stopping warfarin pre-operatively in warfarinised patients with femoral neck fractures. Surgery was more likely to be delayed in these patients. The aim of this retrospective study was to determine the trend of INR level after stopping warfarin and to determine the morbidity and mortality in these patients.

Material and Methods: All patients with femoral neck fracture who were on warfarin between 01.01.2002 and 31.12.2003 were included. Case notes and haematology reports were reviewed.

Results: 22 (4.2%) out of 533 patients with femoral neck fractures were found to be on warfarin on admission. 21 case notes were obtained. 7 male and 14 females with mean age of 81 years. In 11 (52%) cases, INR level increased before coming down after stopping warfarin. 60% of them had morphine as analgesic compared to 40% in the other group. Average rise in INR was 0.4. Average delay in surgery due to high INR was 3.5 (range 1–8) days. It took average of 4 days to achieve desirable INR after restarting warfarin. 6 (28%) needed blood transfusion. Nine (43%) patients developed complications including: intra-operative bleeding-1, postoperative DVT-1, fast AF-2, post-operative anaemia-1, other medical-3. One patient (5%) died from large CVA 12 days after surgery. No further mortality was found within 30 days of surgery.

Conclusion: Incidence of femoral neck fractures on warfarin was 4.2%. In over half of the cases, the INR level went up before going down after stopping warfarin. Morphine may be responsible for this trend. Delay in surgery does not seem to increase mortality or morbidity compared to published studies.